Brokers Set Expectations for Spyglass Pharma FY2025 Earnings

Spyglass Pharma, Inc. (NASDAQ:SGP) – Research analysts at HC Wainwright issued their FY2025 EPS estimates for Spyglass Pharma in a report released on Tuesday, March 10th. HC Wainwright analyst Y. Chen expects that the company will post earnings of ($19.06) per share for the year. HC Wainwright has a “Buy” rating and a $37.00 price objective on the stock. HC Wainwright also issued estimates for Spyglass Pharma’s Q4 2025 earnings at ($6.61) EPS, Q1 2026 earnings at ($0.92) EPS, Q2 2026 earnings at ($0.49) EPS, Q3 2026 earnings at ($0.49) EPS, Q4 2026 earnings at ($0.49) EPS and FY2026 earnings at ($2.21) EPS.

A number of other brokerages also recently issued reports on SGP. Zacks Research raised shares of Spyglass Pharma to a “hold” rating in a report on Wednesday, March 4th. Leerink Partners cut shares of Spyglass Pharma to a “market perform” rating in a research note on Tuesday, March 3rd. Jefferies Financial Group started coverage on shares of Spyglass Pharma in a report on Tuesday, March 3rd. They issued a “buy” rating and a $62.00 price target for the company. Stifel Nicolaus assumed coverage on shares of Spyglass Pharma in a report on Tuesday, March 3rd. They issued a “buy” rating and a $42.00 price target on the stock. Finally, Wall Street Zen raised Spyglass Pharma to a “hold” rating in a research note on Tuesday, February 17th. Five research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat, Spyglass Pharma has a consensus rating of “Moderate Buy” and a consensus target price of $45.00.

Spyglass Pharma Stock Down 2.5%

SGP stock opened at $26.42 on Thursday. Spyglass Pharma has a twelve month low of $20.16 and a twelve month high of $32.44.

Insider Activity at Spyglass Pharma

In other news, Director Ra Capital Management, L.P. purchased 3,690,000 shares of the company’s stock in a transaction on Monday, February 9th. The stock was purchased at an average price of $16.00 per share, with a total value of $59,040,000.00. Following the completion of the purchase, the director directly owned 5,966,439 shares in the company, valued at approximately $95,463,024. This trade represents a 162.10% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Key Headlines Impacting Spyglass Pharma

Here are the key news stories impacting Spyglass Pharma this week:

• Positive Sentiment: HC Wainwright initiated coverage with a “Buy” rating and a $37 price target, which can attract new institutional interest and provide a valuation anchor for the stock. Spyglass Pharma (NASDAQ:SGP) Coverage Initiated at HC Wainwright
• Positive Sentiment: Spyglass announced positive 12‑month topline results from its Phase 1/2 trial of the BIM‑IOL system — a clinical milestone that de‑risks the program and supports future commercialization/value capture if subsequent data and regulatory paths remain favorable. SpyGlass Pharma Announces Positive Topline 12-Month Phase 1/2 Trial Results for Its Innovative BIM-IOL System
• Positive Sentiment: A separate report cites analysts setting a $47 price target on SGP, signaling that some coverage models view substantially higher upside than current levels. That can support speculative buying and re-rate potential. Analysts Set Spyglass Pharma, Inc. (NASDAQ:SGP) Price Target at $47.00
• Neutral Sentiment: HC Wainwright published detailed EPS forecasts across multiple quarters and years while maintaining the Buy rating; the update provides a clearer earnings trajectory for modelers but is a reiteration of analyst coverage rather than new corporate guidance. MarketBeat SGP coverage summary
• Negative Sentiment: HC Wainwright’s EPS projections show large near‑term losses (e.g., FY2025 forecast of roughly ($19.06) and continued quarterly losses in 2026), highlighting significant expected cash burn/dilution risk. Those sizable loss estimates can weigh on the stock despite positive clinical news and Buy ratings — and likely help explain downward pressure today. MarketBeat SGP coverage summary

Spyglass Pharma Company Profile

We are a late-stage biopharmaceutical company dedicated to transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. Our mission is to significantly improve the lives of patients with chronic eye conditions by developing durable drug delivery solutions that can empower patients and surgeons with confidence in long-term disease control and vision preservation. Our lead product candidate, the Bimatoprost Drug Pad-IOL System (BIM-IOL System), comprising novel, proprietary drug pads attached to our intraocular lens (IOL), is designed to be implanted during routine cataract surgery to reduce elevated intraocular pressure (IOP) in patients who have either open-angle glaucoma (OAG) or ocular hypertension (OHT).